These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2039015)

  • 1. The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers.
    Weinberger MH
    Am J Med; 1991 May; 90(5A):15S-20S. PubMed ID: 2039015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive effects of diuretics or sodium restriction with calcium channel blockers in the treatment of hypertension.
    Weinberger MH
    J Cardiovasc Pharmacol; 1988; 12 Suppl 4():S72-5. PubMed ID: 2468879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of atrial natriuretic peptide in the diuretic effect of Ca2+ entry blockers.
    Shamiss A; Peleg E; Rosenthal T; Ezra D
    Eur J Pharmacol; 1993 Mar; 233(1):113-7. PubMed ID: 8472740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
    Antza C; Stabouli S; Kotsis V
    Vasc Health Risk Manag; 2016; 12():443-451. PubMed ID: 27895487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008117. PubMed ID: 24488616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
    Lazich I; Bakris GL
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):471-5. PubMed ID: 21709549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension.
    Levi-Marpillat N; Macquin-Mavier I; Tropeano AI; Parati G; Maison P
    Hypertens Res; 2014 Jun; 37(6):585-90. PubMed ID: 24671016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of calcium-entry blockers and diuretics in the treatment of hypertensive patients.
    Sowers JR; Mohanty PK
    Circulation; 1987 Jun; 75(6 Pt 2):V170-3. PubMed ID: 3552313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension.
    Morgan TO; Anderson AI; MacInnis RJ
    Am J Hypertens; 2001 Mar; 14(3):241-7. PubMed ID: 11281235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin, calcium metabolism and the pathophysiologic basis of antihypertensive therapy.
    Resnick LM; Laragh JH
    Am J Cardiol; 1985 Dec; 56(16):68H-74H. PubMed ID: 2866707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension management: rationale for triple therapy based on mechanisms of action.
    Neutel JM; Smith DH
    Cardiovasc Ther; 2013 Oct; 31(5):251-8. PubMed ID: 23121769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy in hypertension.
    Cappuccio FP; MacGregor GA
    J Hum Hypertens; 1991 Dec; 5 Suppl 2():9-14; discussion 14-5. PubMed ID: 1686467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium channel blockers and hypertension: evolving perspective--1996.
    Epstein M
    Cardiovasc Drugs Ther; 1997 Jan; 10 Suppl 3():883-91. PubMed ID: 9126678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
    Schmieder RE
    Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are there benefits to specific antihypertensive drug therapy?
    Cushman WC
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):31S-35S. PubMed ID: 14625158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channel blockers in cardiovascular pharmacotherapy.
    Godfraind T
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):501-15. PubMed ID: 24872348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.